HekeTiss obtained regulatory authorization and ethics approval to initiate its first-in-human Phase I/IIa clinical trial (RESCUE-PATCH), evaluating TrophiPatch in chronic, non-healing wounds.

The study was authorized by Swissmedic and approved by the Commission cantonale d’éthique de la recherche (CCER), confirming the scientific and regulatory robustness of the development program.

This milestone enabled the initiation of clinical trial activities, including site preparation, operational setup, and readiness for patient inclusion.